STRATA Skin Sciences, Inc. · OTC:SSKN

STRATA Skin Sciences — Investor Presentation (January 2019)

27 slides from STRATA Skin Sciences's investor presentation, Jan 7, 2019

  1. Slide 1: January 2019 Investor Presentation: Driving Value to Dermatology Partners

    January 2019 Investor Presentation Driving Value to Dermatology Partners Matching Patients and Clinics

  2. Slide 2: Safe Harbor Statement

    This presentation includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks, uncertainties and other factors. All statements other than statements of historical fact are statements that could be deemed forward-looking s

  3. Slide 3: STRATA Investment Highlights

    STRATA Investment Highlights Seasoned Management Team – with Deep Domain KnowledgeDr. Dolev Rafaeli, CEO returns with the Accelmed transaction Excimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Eczema, Atopic Dermatitis and Leukoderma Large Market Opportunity Over 35 Million av

  4. Slide 4: XTRAC Revenue Growth Strategy

    XTRAC Revenue Growth Strategy 8n6 Protocol Treatment *RDX – Reimbursement Database XTRAC (proprietary system) REOCCURRENCE DTC ADVERTISING ASSIGNING A DOCTOR PARTNER PATIENTAPPOINTMENT TREATMENT WIN WIN WIN DOCTOR PATIENT STRATA (AND PAYER) INTEREST CREATION IN-HOUSE CALL CENTER INSURANCE ADVOCACY V

  5. Slide 5: XTRAC DTC Advertising

    XTRAC DTC Advertising Vary ye Psori: © acatasa 300-874-8762 Usektrac.com XTRAC = STRATA

  6. Slide 6: Lead Generation is a Business Driver

    Lead Generation is a Business Driver Patient leads in one quarterLeads turn into appointmentsAppointments lead to XTRAC partner revenueOther revenue for the partner clinicRevenue for STRATA 6 NYC, NJ, Long Island

  7. Slide 7: DTC Initial Results – Reduced Acquisition Costs

    DTC Initial Results – Reduced Acquisition Costs Total Likes Total Reach 7

  8. Slide 8: The Market Opportunity

    The Market Opportunity XTRAC cleared in four indications PsoriasisVitiligoEczema and Atopic DermatitisLeukodermaOver 35 million domestic patients3 CPT codes ($150 - $250 based on BSA)$170 average reimbursement rate per treatmentClinical Protocol – 6.2 treatments to PASI 75 Average of 23 treatments p

  9. Slide 9: Excimer Laser Technology - XTRAC / VTRAC

    Excimer Laser Technology - XTRAC® / VTRAC® TechnologyXTRAC excimer laser uses highly targeted (308nm) beam of UVB light to treat affected skin area without damaging surrounding tissueVTRAC is a lamp based 308nm laserTreatment avoids side effects, cost of biologics and messy topicalsTreatments are sa

  10. Slide 10: How XTRAC Works - Psoriasis

    How XTRAC Works - Psoriasis After 4 tx After 2 tx Baseline Beam of UVB light applied to the affected area UVB light induces apoptosis of the keratinocytes and T cells in the dermis Promotes immunosuppression Induces alterations in cytokine profile 140+ peer reviewed published clinical studies 10

  11. Slide 11: How XTRAC Works - Vitiligo

    How XTRAC Works - Vitiligo 11 Long-term skin condition characterized by patches of skin losing its pigment Disease is believed to be due to genetic susceptibility where the autoimmune disease is then triggeredPotentially the immune system is attacking and destroying melanocytes of the skinLife-alter

  12. Slide 12: Domestic Market: Installed Base Overview

    Domestic Market: Installed Base Overview 750 Partner XTRAC 138 sold XTRAC 4 Regions 22 Sales Territories 15 Field Service Techs In-house call center to qualify leadsOnly one competitor in U.S. 12 Territories color coded

  13. Slide 13: International Market: Installed Base

    International Market: Installed Base OUS sales are through distribution with no current recurring revenue model appliedMajor Markets – China, Japan, Saudi Arabia, South KoreaInsurance covered in most marketsUsage/device higher than domestic market – untapped potential in U.S.Over 1,200 OUS devices s

  14. Slide 14: Turnaround Strategy

    Turnaround Strategy DOMESTIC MARKET OUS MARKETS Enhance technology offeringExpand geographical reach in certain markets Rebuild XTRAC value proposition for partner dermatologistsDTC is a revenue driver: Online and offline advertisement, in-house call centerPatient Communication: For both referrals a

  15. Slide 15: Transformative Transaction – Back to the Future

    Transformative Transaction – “Back to the Future” Based on STRATA 10-k Annual Report; Dec 31, 2017 and quarterly filings* STRATA bought XTRAC business from PhotoMedex in 2015 15 Note the numbers prior to Jan 1, 2018 do not reflect adjustments for the adoption Of ASC 606

  16. Slide 16: Media Spend to Recurring XTRAC Treatment Revenue: The Opportunity

    Media Spend to Recurring XTRAC Treatment Revenue: The Opportunity Based on STRATA and PhotoMedex Investor Presentations* STRATA bought XTRAC business from PhotoMedex in 2015 16

  17. Slide 17: Financial Metrics

    Financial Metrics (in thousands except for Average Recurring Revenue per Consigned Systems and Systems Placed under Recurring Revenue Model) Q12017__Q22017__Q32017 042017 Qi2018 _Q2 2018 Dermatology recurring procedures revenue $5556 $ 5971 $ 5525/$ 5588 $ 4498 $ 5,167 Dermatology procedures equipme

  18. Slide 18: Changing Dynamic in Healthcare – Clinic Roll-Ups

    Changing Dynamic in Healthcare – Clinic Roll-Ups* Mapped 1,200 PE and private national group roll ups 38 different groups identifiedXTRAC placement penetration 86 - 8% - Huge OpportunityAugust 20, 2018 – Company announces “Strategic Agreement with a Large Private Equity Backed Group of Dermatology C

  19. Slide 19: Current Clinical Protocol For Optimal Patient Outcomes: 8N6 Protocol

    Current Clinical Protocol For Optimal Patient Outcomes: 8N6 Protocol 01 Twice a week: Minimum 8 visits in 6 weeks 02 Starting dose of at least 300 mj 03 Increase Dose over Time 04 Patient Returns: At least 8 visits per patient 05 …and management of the database to track results 19

  20. Slide 20: Maximizing Dermatologist Partner Clinical Revenue

    Maximizing Dermatologist Partner Clinical Revenue Data collected directly from the lasers demonstrates the importance of following treatment guidelines Revenue = # of lasers x # of treatments/pt x # patients x cost/tx x recurrence factor 20

  21. Slide 21: Optimal Therapeutic Dose (OTD) – 510(k) Received August 2018

    Optimal Therapeutic Dose (“OTD”) – 510(k) Received August/2018The Path to Optimal Clinical Outcomes and Patient Retention MECHANISMTip applies 4 simultaneous doses of energy to the patient’s plaque PURPOSETo minimize number of treatments to clearance USEDose allows provider to determine blister thre

  22. Slide 22: October 2018 – OTD Clinical Study – Launch of XTRAC S3 OTD

    October 2018 – OTD Clinical Study – Launch of XTRAC S3 OTD 92% of the included participants responded to treatment by achieving a reduction in mPASI score of 75% or moreCompared to current average of 16-20 treatments with NB-UVB 308nm devices, OTD treatment produced statistically significant mPASI i

  23. Slide 23: Strong Leadership Team

    Strong Leadership Team 23 Dr. Dolev Rafeli Chief Executive Officer Dr. Uri Geiger Chairman of the Board Matthew C. Hill Chief Financial Officer Dr. Daniel Siegel Consultant

  24. Slide 24: Recent Financial Highlights

    Recent Financial Highlights Q2Q3 24 Total Revenue $7.5 million +17% versus Q1 2018 Recurring XTRAC Revenue $5.2 million +15% versus Q1 2018 Gross Margin 54% +5% versus Q1 2018 Dermatology Recurring Procedures Revenue Margin 64% +7% versus Q1 2018 Total Revenue $7.9 million +8% versus Q3 2017 Recurri

  25. Slide 25: Financial Profile

    Financial Profile Shares and Share Equivalents – Market cap*- $96M (As of Jan 2, 2019) * On an as converted basis of the convertible preferred stock** Does not include 2.4M warrants with a weighted average exercise price of $5.22 as of September 30, 2018 of which 1.6M expire in the first 7 months of

  26. Slide 26: STRATA Investment Highlights

    STRATA Investment Highlights Seasoned Management Team – with Deep Domain KnowledgeDr. Dolev Rafaeli, CEO returns with the Accelmed transaction Excimer Laser Technology for Dermatology IndicationsPsoriasis, Vitiligo, Eczema, Atopic Dermatitis and Leukoderma Large Market Opportunity Over 35 Million av

  27. Slide 27: January 2019 Driving Value to Dermatology Partners

    January 2019 Investor Presentation Driving Value to Dermatology Partners Matching Patients and Clinics

STRATA Skin Sciences — Investor Presentation (January 2019) on 6ix